about
Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia.Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse.Investigating the Extremes of Antibiotic Use with an Epidemiologic FrameworkEvaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.Doses, durations, and gender predict vancomycin-induced kidney injury in pre-clinical studies.High-Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin.Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Pharmacokinetics of centhaquin citrate in a rat model.Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing.Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection.Pharmacokinetics of centhaquin citrate in a dog model.Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia.Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations.Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysisOptimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillinsComparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury
P50
Q35855402-E368AA9F-39BD-4333-BBCA-16B75DC900CCQ36571839-C98A3031-0D43-4CAF-AB21-F36647518F86Q36933322-370FCA85-74A8-4CE7-9F1A-CFA06ACF44BCQ37287667-63E0635F-542F-4124-B050-70C540857F1BQ38625062-183022B7-F5FE-4CB9-AD58-D1B4DD4BEC01Q38627075-3196136E-DF9E-478F-94EB-D45A33E7B807Q38662969-56D77C2C-3372-4631-BE48-66AEC788B1DEQ38698374-135445E3-CA58-46DE-A557-5512ED62F449Q38751264-D722EAB3-97DB-4E68-82CC-40FB9B4326D0Q40149941-C4C3D07F-57EC-4027-8C66-6CFF93619B15Q40363114-50F5060B-AB58-4A3A-BF3F-832FA5164247Q40586250-46B2C8A0-AA63-434F-9689-61CD49684EE1Q49702690-DB1EED97-BC3F-4399-A71A-32B963FD45ADQ50660109-62D163F8-CB06-45D2-A6FB-9FD493EEABA8Q52670587-1825F6C6-CF99-4763-8DB5-F136C1B07DFEQ53187811-9F051136-A1F6-4550-885A-36281B9A6A94Q57779598-0A0CA3EF-3693-4721-933B-6828AC52594DQ90807793-942BAA4D-CE7E-4F4B-8C8C-31F9909AA7A0Q93110539-B9D69DF4-5A37-4684-AEA5-C6784EAB980C
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-5184-1385
@en
name
J Nicholas O'Donnell
@ast
J Nicholas O'Donnell
@en
J Nicholas O'Donnell
@es
J Nicholas O'Donnell
@nl
type
label
J Nicholas O'Donnell
@ast
J Nicholas O'Donnell
@en
J Nicholas O'Donnell
@es
J Nicholas O'Donnell
@nl
prefLabel
J Nicholas O'Donnell
@ast
J Nicholas O'Donnell
@en
J Nicholas O'Donnell
@es
J Nicholas O'Donnell
@nl
P106
P1153
57037930300
P31
P496
0000-0001-5184-1385